Mergers & acquisitions
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here’s more about it.
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
PRESS RELEASES